Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | The potential of biosimilars in cancer treatment

Richard Markus • 26 Sep 2017
ESMO 2017
General

Biosimilars are a promising new addition as a novel treatment option for patients of cancer. Richard Markus, MD, PhD, from Amgen, Los Angeles, CA shares with us his feelings on the attention that biosimilars are gaining from experts in the field, and explains their importance as a new class for cancer treatment. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.

More from Richard Markus

1:01
How were biosimilars discussed at ESMO 2017?
Richard Markus • 26 Sep 2017
1:05
Critical data points in the production of biosimilars
Richard Markus • 26 Sep 2017
0:32
What can biosimilars offer us?
Richard Markus • 26 Sep 2017

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
3:10
PALOMA: subcutaneous amivantamab in advanced solid tumors
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals